MarketCap
Facebook
X
TelegramAzurRx BioPharma, Inc. General and Administrative Expenses 2011-2026 | AZRX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses AzurRx BioPharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 7.29 M | 6.06 M | 8.24 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.24 M | 6.06 M | 7.2 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 219.68 | 1.92 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Seres Therapeutics
MCRB
|
87.7 M | $ 8.28 | - | $ 1.06 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 19.45 | 1.14 % | $ 909 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Mesoblast Limited
MESO
|
21.6 M | $ 15.44 | 7.82 % | $ 10 B |  Australia |
 |
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
27.8 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
5.94 M | $ 0.67 | -5.25 % | $ 7.67 M | Israel |
 |
Mirum Pharmaceuticals
MIRM
|
257 M | $ 90.39 | 2.86 % | $ 4.54 B | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.34 | 1.52 % | $ 342 M | Britain |
 |
MediciNova
MNOV
|
6.16 M | $ 1.45 | - | $ 71.1 M | USA |
 |
CytomX Therapeutics
CTMX
|
29.8 M | $ 4.37 | 2.95 % | $ 603 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
5.39 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
78.9 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.69 | 1.37 % | $ 16.9 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
170 M | - | - | $ 2.02 B | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
17.9 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Merck & Co.
MRK
|
10.7 B | $ 117.56 | 1.02 % | $ 294 B | USA |
 |
Marker Therapeutics
MRKR
|
4.18 M | $ 1.37 | 8.73 % | $ 21 M | USA |
 |
Moderna
MRNA
|
1.02 B | $ 53.09 | 3.41 % | $ 20.7 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
15.9 M | $ 4.47 | 3.71 % | $ 856 M | Canada |
 |
Homology Medicines
FIXX
|
17.7 M | - | 0.77 % | $ 53.4 M | USA |